

Review

Immunotherapy of Cancer through Targeting of the p53 Tumor Antigen

SANDER ZWAVELING^{1, 2}, SJOERD H. VAN DER BURG¹, ANAND G. MENON¹, CORNELIS J. M. MELIEF¹
and RIENK OFFRINGA^{1*}

¹ Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Tumor Immunology Group and ² Department of Surgery, Albinusdreef 2, 2333 ZA Leiden, The Netherlands

Abstract. The expression of the p53 tumor suppressor protein is frequently increased in a great variety of human cancers, making this antigen an attractive candidate for targeting therapeutic T cell immunity. However, potential complications as a result of immunological tolerance or autoimmune pathology must be taken into account when exploiting this ubiquitously expressed auto-antigen for the immunotherapy of cancer.

Key words: cancer immunotherapy; p53 tumor antigen.

Introduction

Despite the development of several alternative strategies to eradicate malignant cells, surgery remains the main option for the curative treatment of solid cancers. It has, however, long been known that adjuvant therapy, following surgery, can prolong life expectancy in human beings with various types of malignancies. Until recently, experience with adjuvant therapy was solely based on chemotherapy or irradiation. In the last decades the potential use of immunotherapy has attracted the attention of researchers. The major advantage of immunotherapy over chemo- and radiotherapy is that it may permit selective elimination of cancer cells in the absence of damage to somatic tissues that are not affected by the disease. T cell-mediated immunotherapy would be particularly suited for this purpose, because T lymphocytes have been shown to specifically recognize and eliminate aberrant tumor cells *in vitro* and *in vivo*. Furthermore, T cells have the capacity to

deeply invade tissues, a property which is important for attacking solid cancers such as colon carcinoma.

Tumor Antigens

Recognition of tumor cells by T lymphocytes requires the expression of tumor-associated antigens and the processing of peptides derived from them into MHC molecules at the tumor cell surface. At present, an impressive number of such tumor-associated antigens has been described³⁸. Several of these antigens are exclusively expressed by tumors and can therefore be exploited as truly tumor-specific targets for anti-tumor T cell immunity. For example, tumors induced by oncogenic viruses (e.g. human papillomavirus type 16-induced cervical carcinoma) express viral antigens that can serve as targets for the T cell responses. However, the majority of human cancers are not associated with the expression of viral antigens. Nevertheless, most

* Correspondence to: Dr. Rienk Offringa, Department of Immunohematology and Blood Transfusion, Albinusdreef 2, 2333 ZA Leiden, The Netherlands, fax: +31 71 521 67 51, e-mail: R.Offringa@LUMC.nl

tumor types do exhibit expression of auto-antigens that are not, or only in a very restricted fashion, expressed by non-transformed somatic cells. This difference may create a therapeutic window that allows T cells to attack tumor cells without killing normal cells. Several studies show that the tumor-associated antigen p53 is aberrantly expressed in approximately 50% of all human malignancies^{23, 74}. Therefore, p53 is a particularly attractive candidate antigen for the targeting of therapeutic anti-tumor immunity.

p53 and Cancer

Wild-type p53 is a tumor suppressor protein that is ubiquitously expressed in normal tissue cells³⁵. Its main function is to guard the structure of the genome, thereby

preventing cells from becoming malignant. Under normal conditions p53 is present in an inactive conformation that is highly susceptible to degradation through the action of proteins such as Mdm2^{24, 39}. As a result, the inactive wild-type p53 has the very short half-life of approximately 20 min⁴⁵ (Fig. 1A). Due to various mechanisms, involving radiation or chemical stress, single- or double-stranded breaks can be introduced in the DNA. Sensory molecules, including DNA-dependent protein kinase (DNA-PK), can subsequently trigger functional activation of p53⁵⁷, causing blockade of the cell cycle and, if the DNA damage is not readily repaired, cell death by apoptosis^{11, 12, 71}. Conversion of p53 to its active conformation causes this protein to become resistant to degradation by Mdm2 and, thereby, to reach higher expression levels^{31, 36, 57} (Fig. 1B).

Since p53 is a pivotal tumor suppressor protein, it




Fig. 1. Regulation of inactive p53 protein (A). Because p53 can induce arrest of cell growth and apoptosis, a tight regulation of its protein levels is required. Particularly the Mdm2 protein is known to be an important regulator of p53. The Mdm2 gene is a transcriptional target of p53 (1), resulting in the upregulation of the encoded Mdm2 protein (2). Subsequently, the Mdm2 targets the p53 (3), thereby not only inhibiting its function as a transcriptional activator (4), but also targeting the p53 protein for proteasome-mediated degradation (5). This autoregulatory feed-back loop can efficiently control p53 levels. Regulation of active p53 protein (B). DNA damage is detected and reported to p53 and Mdm2 by a cascade of sensory molecules, including DNA-PK (1). As a result, both p53 and Mdm2 are phosphorylated, preventing the binding of the two proteins (4). Because Mdm2 is still transcribed (2, 3), this results in coexisting high levels of p53 and Mdm2 (4, 5). When the DNA damage is repaired, the p53 and Mdm2 are dephosphorylated. Under these conditions the high levels of Mdm2 assure a rapid breakdown of the high amount of p53. Disturbed regulation of mutated p53 protein (C). The enhanced stability of mutated p53 is not an intrinsic feature of the aberrant protein, but merely the result of failure of the autoregulatory feed-back loop by Mdm2. Mutant p53 cannot efficiently transcribe Mdm2, leading to low amounts of this protein (1, 2). Moreover, the binding of Mdm2 to mutant p53 is disturbed (3). Consequently, accumulation of the non-functional mutant p53 can be detected (3, 4). mt.p53 stands for mutant p53

is not surprising that mutation of the p53 gene is one of the most frequently occurring events in human oncogenesis²³. Another consequence of p53 gene mutation is disruption of the normal homeostatic pattern of the protein. Mdm2 cannot degrade mutated p53 and, therefore, the non-functional protein can accumulate to high levels (Fig. 1C). Overexpression of p53 is frequently found in many types of human cancers, including colorectal carcinomas (Fig. 2), prompting research concerning the possibility to use p53 as a target antigen for immunotherapeutic intervention against cancer.

p53-Specific Immunity

The detection of antibodies against p53 in mice bearing mutant p53-overexpressing tumors provided

the first clue that the immune system can respond against the p53 protein^{10, 34}. Likewise, antibodies against p53 have frequently been detected in the sera of cancer patients, including patients with colorectal carcinoma^{1, 9}. The presence of these antibodies proved to be an indicator of poor prognosis²⁶ and most likely reflects an abundant release of tumor-derived p53 in patients with large disseminated tumors and, thereby, an increased availability of this antigen for the activation of B cells. However, an anti-tumor efficacy of these antibodies is precluded by the fact that p53 is an intracellular antigen that is not expressed at the cell surface. Importantly, peptides derived from p53 through proteolytic degradation can be presented on the cell surface in the context of MHC class I or II, thereby serving as potential targets for T cells.




Fig. 2. Overexpression of p53 in colon carcinoma. The p53 protein is often overexpressed in many tumor types, such as colon carcinoma. In the depicted section of a colorectal cancer, the p53 protein is stained with a p53-specific antibody. Clearly, the tumor cells overexpress p53, while the stroma cells do not

Immunological Tolerance of p53

Immunological tolerance creates a potential hurdle for the use of auto-antigens such as p53 as a target for T cell-mediated immunotherapy against cancer. The p53 protein is ubiquitously expressed in all body cells and, therefore, also in the thymus⁴⁷. Consequently, high affinity T cells reacting against this self-antigen may be deleted from the T cell repertoire. Because tumors often express mutated p53, tolerance could be circumvented by targeting of the mutated areas of the protein, which can be considered as “non-self”. However, the mutations occurring in the p53 protein are very heterogeneous. Identification of the mutations would be required for every individual patient prior to immunotherapy. Moreover, the mutations are rarely contained within the processed p53-derived peptides that are presented in MHC molecules⁷², rendering this approach far from generally applicable. Tumor immunological research has therefore focused on the use of wild-type p53 as a target for T cell-mediated immunotherapy. The potential of this strategy was illustrated by the finding of wild-type p53-specific T helper (Th) cells in patients with colorectal cancer⁶⁸. In addition, cytotoxic T lymphocytes (CTL) and Th cells against wild-type p53 could be isolated from peripheral blood mononuclear cell (PBMC) cultures of healthy subjects^{3, 7, 17, 25, 49}. Together with the outcomes of studies in mouse models, in which p53-specific vaccination raised wild-type p53-specific T cell immunity^{29, 37, 51}, these data indicate that tolerance against p53 is not complete and that exploitation of the p53-specific T cell repertoire for the immunotherapy of cancer may be feasible.

Split-Tolerance for p53

Although protective immunity against p53-overexpressing tumors could be achieved in 4 studies in mice following p53-specific vaccination^{28, 37, 51, 65, 66}, only one of these studies provided direct evidence that this was the result of p53-specific CTL activity³⁷. In several other studies involving the analysis of p53-specific CTL, the anti-tumor efficacy of p53-specific CTL was only demonstrated *in vitro*, not *in vivo*^{13, 14, 18, 21, 26, 40, 49, 61}. Furthermore, it was shown that in the periphery of p53^{+/+} mice only low avidity CTL against p53 could be found^{20, 21, 62}. With regard to the tremendous effort put into the induction of p53-specific CTL, these results are rather meager, suggesting that tolerance for p53 at the CTL level may be hard to break. There is convincing evidence that tolerance is far less pronounced in the

case of p53-specific Th responses. The fact that antibody responses of the p53-specific IgG-type are found spontaneously in the sera of tumor-bearing mice and cancer patients points to a Th cell component, because class switching from IgM to IgG antibodies requires the involvement of CD4⁺ T cells^{5, 8}. Moreover, various studies clearly indicate the existence of p53-specific Th immunity in humans^{17, 63, 68}. Recently, we (ZWAVELING et al., Cancer Res., in press) and others¹⁵ demonstrated in a preclinical model in mice the lack of tolerance for p53 at the Th cell level. Furthermore, we showed that a p53-specific Th line can assist in clearing p53-overexpressing tumors *in vivo*. The intriguing difference found for p53-specific CTL and Th tolerance can be explained by taking into account the metabolism of wild-type p53. Under normal circumstances, the p53 protein has a very high turnover, as it becomes rapidly degraded via the ubiquitin- and proteasome-dependent pathway². It is highly conceivable that this degradation pathway efficiently feeds p53-derived peptides into the MHC class I presentation pathway, enabling normal somatic cells, including thymic antigen-presenting cell (APC), to present these peptides at their surface (Fig. 3A). In contrast, the dominance of the proteasome-dependent degradation will not leave a considerable amount of p53 available for direct or cross-presentation through the MHC class II-processing pathway. These circumstances make it very unlikely that, in a healthy subject, p53-derived peptides are presented in the context of MHC class II, either in the thymus or the periphery, thereby explaining the lack of tolerance at the Th level⁴¹ (Fig. 3B).

Anti-Tumor Efficacy vs Autoimmune Pathology

Apart from tolerance, another potential complication that must be considered with the use of wild-type p53 as a target for T cell-mediated immunity is the danger of inducing autoimmunity. The p53 protein is expressed, albeit at low levels, throughout the body and the consequences of an uncontrolled immune response against p53 could be disastrous. Importantly, we have demonstrated that high-affinity wild-type p53-specific CTL, isolated from p53 knock-out mice, can eradicate p53-overexpressing tumors in p53^{+/+} mice in the absence of immune pathological damage to normal tissue cells⁷⁰. Similarly, the *in vivo* action of p53-specific Th cells against p53-overexpressing tumors did not coincide with autoimmune pathology (ZWAVELING et al., Cancer Res., in press). Therefore, we can conclude that the difference in p53 expression between tumors and




Fig. 3. Antigen presentation via the MHC class I pathway (**A**). All normal tissue cells endogenously express self antigens such as p53. Following degradation by the proteasome, antigen-derived peptides can be presented by MHC class I molecules on the cell surface. The presence of antigen-specific CD8⁺ T cells, recognizing these peptides, would consequently lead to autoimmunity. Therefore, maturing CD8⁺ cells that recognize these self antigens have to be deleted from the T cell repertoire in the thymus prior to their systemic release. APC in the thymus are responsible for this negative selection process. Like other cells, the APC can express self antigens, including p53, in a MHC class I context. Upon recognition of these antigen-derived peptides, maturing CD8⁺ cells are mainly deleted from the T cell repertoire via a process that is not yet fully identified. Antigen presentation via the MHC class II pathway (**B**). APC do not only express MHC class I molecules, but also MHC class II molecules. Proteins obtained from the exterior environment (e.g. proteins derived from dead cells) can be taken up by APC via endocytosis. The proteins are degraded by various proteases in the lysosome and subsequently presented in a MHC class II context on the cell surface of the APC. Due to the highly efficient degradation of p53, this protein will usually not be present in the debris obtained from dead cells. Therefore, the pathway leading to presentation of p53-derived peptides in MHC class II will not take place and, as a result, no p53-derived peptides will be presented by MHC class II molecules on APC to CD4⁺ cells. Consequently, maturing p53-specific CD4⁺ T cells will not be deleted from the repertoire in the thymus. When a p53-overexpressing tumor develops, high amounts of stable p53 will become available, due to necrosis and apoptosis of tumor cells, for processing and presentation in the MHC class II pathway of APC in the vicinity of the tumor. Since p53-specific CD4⁺ T cells have not been deleted from the T cell repertoire, this will lead to recognition of the p53 protein by these T helper cells

normal tissue creates a therapeutic window. In accordance with this notion, a recent phase I/II clinical trial performed at our institute showed that patients vaccinated with recombinant canarypox virus (ALVAC) encoding wild-type human p53 elicited p53-specific T cell immunity in the absence of detectable autoimmune pathology⁶⁹. Previous immunization studies with ALVAC-p53 in mice and primates had shown similar results^{50, 51}. Although these data demonstrate that autoimmunity can be avoided while T cell responses against p53 are successfully raised, application in humans of vaccines aimed at eliciting p53-specific T cell responses should still be conducted with great care.

A Role for p53-Specific T Helper Cells

So far, the efforts of raising p53-specific immune responses have primarily focused on CTL. Because tolerance against p53-specific Th cells appears to be less restricted than tolerance against p53-specific CTL, it is of interest to further explore the anti-tumor efficacy of the p53-specific Th component. Although most solid tumors do not express MHC class II, thereby excluding cognate interactions between Th cells and tumor cells, it is by now evident that Th cells contribute essentially to the eradication of such tumors^{38, 42, 48, 55, 64}. This help can act through the recruitment of tumoricidal macrophages and eosinophils^{19, 27}, but also through CTL-dependent mechanisms involving the delivery of essential

growth stimuli to CTL³⁰ and the triggering of APC through CD40-CD40 ligand interactions^{4, 46, 56}. The latter mechanism induces antigen-presenting dendritic cells (DCs) to fully display their antigen-presenting and costimulatory functions, providing naïve CTL with a “license to kill” signal, and requires the DC to present relevant epitopes in the context of both MHC class I and class II. Several studies by others^{6, 22, 33, 43, 58} and us⁷⁵ have indeed demonstrated the superiority of vaccines comprising tumor-specific CTL and Th epitopes over comparable vaccines containing CTL epitopes only. Importantly, these epitopes do not have to be derived from the same antigen⁴², implying that p53-specific Th cells can also enable the activation of CTL directed against tumor-associated antigens other than p53. The strategy of evoking p53-specific Th cells in combination with CTL directed against other tumor-specific antigens therefore deserves further exploration.

Targeting of p53 in Colorectal Cancer

Colorectal cancer is the second cause of cancer-related death in the developed part of the world, following lung cancer in males and breast cancer in females. Because the perspectives for patients with metastases, for whom chemotherapy is at present basically the only option, are rather bleak, T cell-mediated immunotherapy against targets such as p53 could provide an important alternative. As mentioned before, the option of raising p53-specific T cells in combination with T cell immunity against other tumor-associated antigens may be feasible. Carcinoembryonic antigen (CEA) or epithelial cell adhesion molecule (Ep-CAM, KSA, 17-1-A), antigens often overexpressed in colorectal carcinoma, are being studied extensively in this respect⁴⁴. In view of the above, a clinical trial involving ALVAC-based vaccination against p53, CEA and Ep-CAM will be performed in colorectal patients in the near future. More recently, several additional wild-type and modified antigens have been proposed as targets for therapeutic T cell immunity against colorectal tumors. These include β catenin, which is frequently overexpressed in colorectal cancers¹⁶, and frameshift mutation-derived peptides from several cellular proteins, for example the transforming growth factor receptor II^{54, 73}.

Directions for Further Research

In order for anti-cancer vaccines to have therapeutic impact in patients, newly designed powerful adjuvants need to be co-administered. In a recent peptide-vaccination study we tested the effect of several of these

adjuvants on the induction of CTL responses⁷⁵. Adjuvants constituting a strong trigger for DC activation, such as CpG oligodeoxynucleotides and MPL, proved capable of raising more vigorous CTL responses than incomplete Freund's adjuvants (IFA, Montanide ISA45). Most importantly, whereas the peptide vaccines in IFA were only capable of inducing protective immunity against a subsequent challenge with tumor cells, the use of such stronger adjuvants upgraded the peptide vaccine to a therapeutic formulation capable of inducing rejection of pre-existing tumors. Some of these DC-activating adjuvants are, or will soon be, available for clinical use. Although more powerful adjuvants can improve the expansion of the desired T cell repertoire, such formulations cannot overcome the lack of certain T cell specificities due to clonal deletion. Nevertheless, several strategies may still allow the exploitation of p53-specific CTL immunity, for instance through the use of allogeneic T cell repertoires that have not been subjected to self MHC-restricted tolerance induction^{52, 53, 60}. CTL against p53 in an allogeneic MHC class I context could be generated from donor-lymphocytes. Subsequent adoptive transfer to cancer patients, who receive bone marrow transplants from this donor beforehand to create a surrounding in which the transferred CTL can survive, may lead to a reduction of the tumor burden. Alternatively, transfer of p53-specific T cell receptor (TCR)-raised in HLA-transgenic p53 knock-out mice, to human CTL precursors should be considered^{32, 59}. Especially TCRs that recognize human wild-type p53-derived peptide epitopes in the context of HLA molecules that are highly prevalent in the human population, such as HLA-A*0201, can constitute highly versatile tools for this approach. Last but not least, several groups have found evidence for the presence of at least a limited p53-specific CTL repertoire in humans^{3, 14, 18, 49, 61}. Together, these findings prompt research concerning the “rules” that allow escape of certain p53-specific CTL from thymic deletion. VAN DEN EYNDE and MOREL⁶⁷ have recently shown that auto-reactive CTL can escape deletion in the thymus if they are directed against epitopes that are exclusively, or at least primarily, formed by constitutive proteasomes and not, or to a much lesser extent, by immunoproteasomes. Because the thymic APC predominantly express immunoproteasomes, the degradation pattern imposed by this enzymatic configuration dominates the peptide repertoires presented to thymocytes during negative selection. In view of these findings, it is of interest to examine whether digestion of human p53-derived peptides by constitutive versus immunoproteasomes would reveal similar differences that

could point to an escape of a p53-specific CTL subset from thymic deletion.

In spite of the fact that new techniques and recent insights have tremendously boosted the development of immunotherapeutic strategies against tumors, the clinical impact of these strategies has so far been very modest. This is partly due to the long process of extensive testing in pre-clinical systems and subsequent clinical trials that is required before approval for clinical use is granted, but could also relate to the difficulties in translating pre-clinical data to a clinical situation. Therefore, at this moment chemotherapy and irradiation are still the main options for the adjuvant therapy of cancer.

Acknowledgment. This work is supported by grants from the Dutch Organization for Scientific Research and from the Dutch Cancer Society. Additional support is obtained from Aventis Pasteur Ltd. The work discussed in this review is supported by the Dutch Cancer Society, the Dutch Organization for Scientific Research and by Aventis-Pasteur.

References

- ANGELOPOULOU K., DIAMANDIS E. P., SUTHERLAND D. J., KELLEN J. A. and BUNTING P. S. (1994): Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. *Int. J. Cancer*, **58**, 480–487.
- ASHCROFT M. and VOUSDEN K. H. (1999): Regulation of p53 stability. *Oncogene*, **18**, 7637–7643.
- BARFOED A. M., PETERSEN T. R., KIRKIN A. F., THOR STRATEN P., CLAESSEON M. H. and ZEUTHEN J. (2000): Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells *in vitro*, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. *Scand. J. Immunol.*, **51**, 128–133.
- BENNETT S. R., CARBONE F. R., KARAMALIS F., FLAVELL R. A., MILLER J. F. and HEATH W. R. (1998): Help for cytotoxic-T-cell responses is mediated by CD40 signaling. *Nature*, **393**, 478–480.
- BERGSTEDT-LINDQVIST S., SIDERAS P., MACDONALD H. R. and SEVERINSON E. (1984): Regulation of Ig class secretion by soluble products of certain T-cell lines. *Immunol. Rev.*, **78**, 25–50.
- BRISTOL J. A., ORSINI C., LINDINGER P., THALHAMER J. and ABRAMS S. I. (2000): Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization. *Cell. Immunol.*, **205**, 73–83.
- CHIKAMATSU K., NAKANO K., STORKUS W. J., APPELLA E., LOTZE M. T., WHITESIDE T. L. and DELEO A. B. (1999): Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. *Clin. Cancer Res.*, **5**, 1281–1288.
- COFFMAN R. L., SEYMOUR B. W., LEBMAN D. A., HIRAKI D. D., CHRISTIANSEN J. A., SHRADER B., CHERWINSKI H. M., SAVEL-KOUL H. F., FINKELMAN F. D., BOND M. W. and MOSMANN T. R. (1988): The role of helper T cell products in mouse B cell differentiation and isotype regulation. *Immunol. Rev.*, **102**, 5–28.
- CRAWFORD L. V., PIM D. C. and LAMB P. (1984): The cellular protein p53 in human tumours. *Mol. Biol. Med.*, **2**, 261–272.
- DELEO A. B., JAY G., APPELLA E., DUBOIS G. C., LAW L. W. and OLD L. J. (1979): Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. *Proc. Natl. Acad. Sci. USA*, **76**, 2420–2424.
- DEL SAL G., MURPHY M., RUARO E., LAZAREVIC D., LEVINE A. J. and SCHNEIDER C. (1996): Cyclin D1 and p21/waf1 are both involved in p53 growth suppression. *Oncogene*, **12**, 177–185.
- DUTTA A., RUPPERT J. M., ASTER J. C. and WINCHESTER E. (1993): Inhibition of DNA replication factor RPA by p53. *Nature*, **365**, 79–82.
- ERDILE L. F. and SMITH D. (2000): CD40 activation enhances the magnitude of cellular immune responses against p53 but not the avidity of the effectors. *Cancer Immunol. Immunother.*, **49**, 410–416.
- EUR A. M., CHIKAMATSU K., KATSURA F., OBATA A., SOBAO Y., TAKIGUCHI M., SONG Y., APPELLA E., WHITESIDE T. L. and DELEO A. B. (2000): A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. *Clin. Cancer Res.*, **6**, 979–986.
- FEDOSEYEVA E. V., BOISGERAULT F., ANOSOVA N. G., WOLLISH W. S., ARLOTTA P., JENSEN P. E., ONO S. J. and BENICHOU G. (2000): CD4+ T cell responses to self and mutated p53 determinants during tumorigenesis in mice. *J. Immunol.*, **164**, 5641–5651.
- FODDE R., SMITS R. and CLEVERS H. (2001): APC, signal transduction and genetic instability in colorectal cancer. *Nat. Rev. Cancer*, **1**, 55–67.
- FUJITA H., SENJU S., YOKOMIZO H., SAYA H., OGAWA M., MATSUSHITA S. and NISHIMURA Y. (1998): Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. *Eur. J. Immunol.*, **28**, 305–316.
- GNJATIC S., CAI Z., VIGUIER M., CHOUAIB S., GUILLET J. G. and CHOPPIN J. (1998): Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. *J. Immunol.*, **160**, 328–333.
- GREENBERG P. D. (1991): Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. *Adv. Immunol.*, **49**, 281–355.
- HERNANDEZ J., KO A. and SHERMAN L. A. (2001): CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. *J. Immunol.*, **166**, 3908–3914.
- HERNANDEZ J., LEE P. P., DAVIS M. M. and SHERMAN L. A. (2000): The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. *J. Immunol.*, **164**, 596–602.
- HIRANUMA K., TAMAKI S., NISHIMURA Y., KUSUKI S., ISOGAWA M., KIM G., KAITO M., KURIBAYASHI K., ADACHI Y. and YASUTOMI Y. (1999): Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. *J. Gen. Virol.*, **80**, 187–193.
- HOLLSTEIN M., SIDRANSKY D., VOGELSTEIN B. and HARRIS C. C. (1991): p53 mutations in human cancers. *Science*, **253**, 49–53.
- HONDA R., TANAKA H. and YASUDA H. (1997): Oncoprotein

- MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. *FEBS Lett.*, **420**, 25–27.
25. HOUBIERS J. G., NIJMAN H. W., VAN DER BURG S. H., DRUHFHOUT J. W., KENEMANS P., VAN DE VELDE C. J., BRAND A., MOMBURG F., KAST W. M. and MELIEF C. J. (1993): *In vitro* induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. *Eur. J. Immunol.*, **23**, 2072–2077.
 26. HOUBIERS J. G., VAN DER BURG S. H., VAN DE WATERING L. M., TOLLENAAR R. A., BRAND A., VAN DE VELDE C. J. and MELIEF C. J. (1995): Antibodies against p53 are associated with poor prognosis of colorectal cancer. *Br. J. Cancer*, **72**, 637–641.
 27. HUNG K., HAYASHI R., LAFOND-WALKER A., LOWENSTEIN C., PARDOLL D. and LEVITSKY H. (1998): The central role of CD4(+) T cells in the antitumor immune response. *J. Exp. Med.*, **188**, 2357–2368.
 28. HURPIN C., ROTARIOA C., BISCEGLIA H., CHEVALIER M., TARTAGLIA J. and ERDILE L. (1998): The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity. *Vaccine*, **16**, 208–215.
 29. ISHIDA T., CHADA S., STIPANOV M., NADAF S., CIERNIK F. I., GABRILOVICH D. I. and CARBONE D. P. (1999): Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. *Clin. Exp. Immunol.*, **117**, 244–251.
 30. KAST W. M., OFFRINGA R., PETERS P. J., VOORDOUW A. C., MELOEN R. H., VAN DER EB A. J. and MELIEF C. J. (1989): Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. *Cell*, **59**, 603–614.
 31. KASTAN M. B., ONYKWERE O., SIDRANSKY D., VOGELSTEIN B. and CRAIG R. W. (1991): Participation of p53 protein in the cellular response to DNA damage. *Cancer Res.*, **51**, 6304–6311.
 32. KESSELS H. W., WOLKERS M. C., VAN DEN BOOM M. D., VAN DER VALK M. A. and SCHUMACHER T. N. (2001): Immunotherapy through TCR gene transfer. *Nat. Immunol.*, **2**, 957–961.
 33. KNOTSON K. L., SCHIFFMAN K. and DISIS M. L. (2001): Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. *J. Clin. Invest.*, **107**, 477–484.
 34. LANE D. P. and CRAWFORD L. V. (1979): T antigen is bound to a host protein in SV40-transformed cells. *Nature*, **278**, 261–263.
 35. LEVINE A. J., MOMAND J. and FINLAY C. A. (1991): The p53 tumour suppressor gene. *Nature*, **351**, 453–456.
 36. MAYO L. D., TURCHI J. J. and BERBERICH S. J. (1997): Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. *Cancer Res.*, **57**, 5013–5016.
 37. MAYORDOMO J. I., LOFTUS D. J., SAKAMOTO H., DE CESARE C. M., APPASAMY P. M., LOTZE M. T., STORKUS W. J., APPELLA E. and DELEO A. B. (1996): Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. *J. Exp. Med.*, **183**, 1357–1365.
 38. MELIEF C. J., TOES R. E., MEDEMA J. P., VAN DER BURG S. H., OSSENDORP F. and OFFRINGA R. (2000): Strategies for immunotherapy of cancer. *Adv. Immunol.*, **75**, 235–282.
 39. MOMAND J., ZAMBETTI G. P., OLSON D. C., GEORGE D. and LEVINE A. J. (1992): The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. *Cell*, **69**, 1237–1245.
 40. NIJMAN H. W., VAN DER BURG S. H., VIERBOOM M. P., HOUBIERS J. G., KAST W. M. and MELIEF C. J. (1994): p53, a potential target for tumor-directed T cells. *Immunol. Lett.*, **40**, 171–178.
 41. OFFRINGA R., VIERBOOM M. P., VAN DER BURG S. H., ERDILE L. and MELIEF C. J. (2000): p53: a potential target antigen for immunotherapy of cancer. *Ann. NY Acad. Sci.*, **910**, 223–233; discussion 233–226.
 42. OSSENDORP F., MENGEDE E., CAMPS M., FILIUS R. and MELIEF C. J. (1998): Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. *J. Exp. Med.*, **187**, 693–702.
 43. PARTIDOS C. D., VOHRA P. and STEWARD M. W. (1996): Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides. *Immunology*, **87**, 179–185.
 44. RAS E., VAN DER BURG S. H., ZEGVELD S. T., BRANDT R. M., KUPPEN P. J., OFFRINGA R., WARNARR S. O., VAN DE VELDE C. J. and MELIEF C. J. (1997): Identification of potential HLA-A*0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). *Hum. Immunol.*, **53**, 81–89.
 45. REICH N. C., OREN M. and LEVINE A. J. (1983): Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. *Mol. Cell. Biol.*, **3**, 2143–2150.
 46. RIDGE J. P., DI ROSA F. and MATZINGER P. (1998): A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. *Nature*, **393**, 474–478.
 47. ROGEL A., POPLIKER M., WEBB C. G. and OREN M. (1985): p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. *Mol. Cell. Biol.*, **5**, 2851–2855.
 48. ROMERDAHL C. A. and KRIPKE M. L. (1988): Role of helper T-lymphocytes in rejection of UV-induced murine skin cancers. *Cancer Res.*, **48**, 2325–2328.
 49. ROPKE M., HALD J., GULDBERG P., ZEUTHEN J., NORGAARD L., FUGGER L., SVEJGAARD A., VAN DER BURG S., NIJMAN H. W., MELIEF C. J. and CLAESSEN M. H. (1996): Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. *Proc. Natl. Acad. Sci. USA*, **93**, 14704–14707.
 50. ROSENWIRTH B., KUHN E. M., HEENEY J. L., HURPIN C., TARTAGLIA J., BONNET M. C., MOINGEON P. and ERDILE L. (2001): Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques. *Vaccine*, **19**, 1661–1670.
 51. ROTH J., DITTMER D., REA D., TARTAGLIA J., PAOLETTI E. and LEVINE A. J. (1996): p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. *Proc. Natl. Acad. Sci. USA*, **93**, 4781–4786.
 52. SADOVNIKOVA E., JOPLING L. A., SOO K. S. and STAUSS H. J. (1998): Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. *Eur. J. Immunol.*, **28**, 193–200.
 53. SADOVNIKOVA E. and STAUSS H. J. (1996): Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. *Proc. Natl. Acad. Sci. USA*, **93**, 13114–13118.
 54. SAETERDAL I., BJORHEIM J., LISLERUD K., GJERTSEN M. K., BUKHOLM I. K., OLSEN O. C., NESLAND J. M., ERIKSEN J. A., MOLLER M., LINDBLOM A. and GAUDERNACK G. (2001):

- Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. *Proc. Natl. Acad. Sci. USA*, **98**, 13255–13260.
55. SCHILD H. J., KYEWSKI B., VON HOEGEN P. and SCHIRRMACHER V. (1987): CD4⁺ helper T cells are required for resistance to a highly metastatic murine tumor. *Eur. J. Immunol.*, **17**, 1863–1866.
 56. SCHOENBERGER S. P., TOES R. E., VAN DER VOORT E. I., OFFRINGA R. and MELIEF C. J. (1998): T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. *Nature*, **393**, 480–483.
 57. SHIEH S. Y., IKEDA M., TAYA Y. and PRIVES C. (1997): DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. *Cell*, **91**, 325–334.
 58. SHIRAI M., PENDLETON C. D., AHLERS J., TAKESHITA T., NEWMAN M. and BERZOFKY J. A. (1994): Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8⁺ CTL *in vivo* with peptide vaccine constructs. *J. Immunol.*, **152**, 549–556.
 59. STANISLAWSKI T., VOSS R. H., LOTZ C., SADOVNIKOVA E., WILLEMSSEN R. A., KUBALL J., RUPPERT T., BOLHUIS R. L., MELIEF C. J., HUBER C., STAUSS H. J. and THEOBALD M. (2001): Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. *Nat. Immunol.*, **2**, 962–970.
 60. STAUSS H. J. (1999): Immunotherapy with CTLs restricted by nonself MHC. *Immunol. Today*, **20**, 180–183.
 61. THEOBALD M., BIGGS J., DITTMER D., LEVINE A. J. and SHERMAN L. A. (1995): Targeting p53 as a general tumor antigen. *Proc. Natl. Acad. Sci. USA*, **92**, 11993–11997.
 62. THEOBALD M., BIGGS J., HERNANDEZ J., LUSTGARTEN J., LABADIE C. and SHERMAN L. A. (1997): Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. *J. Exp. Med.*, **185**, 833–841.
 63. TILKIN A. F., LUBIN R., SOUSSI T., LAZAR V., JANIN N., MATHIEU M. C., LEFRERE I., CARLU C., ROY M., KAYIBANDA M., BELLET D., GUILLET J. G. and PAILLERETS B. B. (1995): Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. *Eur. J. Immunol.*, **25**, 1765–1769.
 64. TOES R. E., OSSENDORP F., OFFRINGA R. and MELIEF C. J. (1999): CD4 T cells and their role in antitumor immune responses. *J. Exp. Med.*, **189**, 753–756.
 65. TUTING T., DELEO A. B., LOTZE M. T. and STORKUS W. J. (1997): Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or “self” antigens induce antitumor immunity *in vivo*. *Eur. J. Immunol.*, **27**, 2702–2707.
 66. TUTING T., GAMBOTTO A., ROBBINS P. D., STORKUS W. J. and DELEO A. B. (1999): Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. *Gene Ther.*, **6**, 629–636.
 67. VAN DEN EYNDE B. J. and MOREL S. (2001): Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. *Curr. Opin. Immunol.*, **13**, 147–153.
 68. VAN DER BURG S. H., DE COCK K., MENON A. G., FRANKEN K. L., PALMEN M., REDEKER A., DRIJFHOUT J., KUPPEN P. J., VAN DE VELDE C., ERDILE L., TOLLENAAR R. A., MELIEF C. J. and OFFRINGA R. (2001): Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. *Eur. J. Immunol.*, **31**, 146–155.
 69. VAN DER BURG S. H., MENON A. G., REDEKER A., BONNET M. C., DRIJFHOUT J. W., TOLLENAAR R. A., VAN DE VELDE C. J., MOINGEON P., KUPPEN P. J., OFFRINGA R. and MELIEF C. J. (2002): Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. *Clin. Cancer Res.*, **8**, 1019–1027.
 70. VIERBOOM M. P., NIJMAN H. W., OFFRINGA R., VAN DER VOORT E. I., VAN HALL T., VAN DEN BROEK L., FLEUREN G. J., KENEMANS P., KAST W. M. and MELIEF C. J. (1997): Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. *J. Exp. Med.*, **186**, 695–704.
 71. WANG X. W., YEH H., SCHAEFFER L., ROY R., MONCOLLIN V., EGLY J. M., WANG Z., FREIDBERG E. C., EVANS M. K., TAFTE B. G. et al. (1995): p53 modulation of TFIIH-associated nucleotide excision repair activity. *Nat. Genet.*, **10**, 188–195.
 72. WIEDENFELD E. A., FERNANDEZ-VINA M., BERZOFKY J. A. and CARBONE D. P. (1994): Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA-A*0201 peptide consensus motif. *Cancer Res.*, **54**, 1175–1177.
 73. WOERNER S. M., GEBERT J., YUAN Y. P., SUTTER C., RIDDER R., BORK P. and VON KNEBEL DOEBERITZ M. (2001): Systematic identification of genes with coding microsatellites mutated in DNA mismatch repair-deficient cancer cells. *Int. J. Cancer*, **93**, 12–19.
 74. ZAMBETTI G. P. and LEVINE A. J. (1993): A comparison of the biological activities of wild-type and mutant p53. *FASEB J.*, **7**, 855–865.
 75. ZWAVELING S., FERREIRA MOTA S. C., NOUTA J., JOHNSON M., LIPFORD G. B., OFFRINGA R., VAN DER BURG S. H., and MELIEF C. J. (2002): Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. *J. Immunol.*, **169**, 350–358.

Received in May 2002

Accepted in June 2002